Current symptomatic treatments include only two classes of approved medications for the treatment of Alzheimer’s disease; i/inhibitors of the enzyme cholinesterase, i.e., donepezil, rivastigmine, or galantamine, and ii/N-methyl-D-aspartate antagonists, i.e., memantine, which are only effective in treating the symptoms of the disease but do not cure or prevent the disease [88,114]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.